US Bancorp DE Purchases 8,129 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

US Bancorp DE grew its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 206.0% during the 3rd quarter, HoldingsChannel reports. The firm owned 12,076 shares of the company’s stock after acquiring an additional 8,129 shares during the quarter. US Bancorp DE’s holdings in iTeos Therapeutics were worth $123,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its stake in iTeos Therapeutics by 6.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares during the period. Creative Planning lifted its holdings in shares of iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after buying an additional 1,196 shares during the last quarter. nVerses Capital LLC boosted its position in shares of iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the period. Public Employees Retirement System of Ohio grew its stake in shares of iTeos Therapeutics by 4.9% in the first quarter. Public Employees Retirement System of Ohio now owns 39,003 shares of the company’s stock worth $532,000 after acquiring an additional 1,817 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in iTeos Therapeutics by 60.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock worth $72,000 after acquiring an additional 2,646 shares during the period. 97.16% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ITOS has been the topic of several research analyst reports. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of iTeos Therapeutics in a research report on Tuesday. Wells Fargo & Company initiated coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Friday. Finally, JPMorgan Chase & Co. decreased their price objective on iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a report on Monday, August 12th.

iTeos Therapeutics Stock Down 2.7 %

NASDAQ ITOS opened at $8.23 on Friday. iTeos Therapeutics, Inc. has a twelve month low of $7.99 and a twelve month high of $18.75. The stock has a market cap of $300.64 million, a P/E ratio of -2.69 and a beta of 1.39. The company’s 50-day simple moving average is $10.40 and its 200 day simple moving average is $13.99.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.